FAQ on Soligenix Inc.'s Rare Disease Innovation and HyBryte(TM) Platform

What is Soligenix Inc. known for?

Soligenix Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with unmet medical needs, including its HyBryte(TM) platform for CTCL and vaccine programs for diseases like COVID-19.

Why is Soligenix’s HyBryte(TM) platform significant?

HyBryte(TM) represents a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL), a rare skin cancer, showcasing Soligenix’s innovation in treating rare diseases and supporting underserved patient populations.

How does HyBryte(TM) work?

HyBryte(TM) is a synthetic hypericin-based treatment that utilizes safe visible light as a novel photodynamic therapy for CTCL, aiming to provide an effective treatment option for this rare cancer.

Who benefits from Soligenix’s therapies?

Patients with rare diseases like CTCL, psoriasis, inflammatory diseases, and those in need of vaccines for ricin toxin, filoviruses, and COVID-19 benefit from Soligenix’s innovative treatments and vaccine programs.

Where can I find more information about Soligenix’s developments?

More information is available on Soligenix’s website at www.Soligenix.com and the latest news at https://ibn.fm/SNGX.

What are the future plans for HyBryte(TM)?

Following the successful completion of the second Phase 3 study, Soligenix plans to seek regulatory approvals for HyBryte(TM) to support potential commercialization worldwide, including expansion into psoriasis treatment.

How is Soligenix’s vaccine program supported?

Soligenix’s vaccine programs, including those for COVID-19 and ricin toxin, are supported by government grants and contracts from NIAID, DTRA, and BARDA, utilizing its proprietary ThermoVax(R) technology.

What makes Soligenix’s approach to rare diseases unique?

Soligenix’s focus on rare diseases with unmet medical needs, combined with its innovative platforms like HyBryte(TM) and ThermoVax(R), demonstrates a commitment to addressing healthcare challenges through domestic innovation and support for underserved populations.